drugset / Trial / NCT02739542

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

NCT02739542

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this investigation is to systematically study the efficacy of Tecfidera in those individuals who possess incidental white matter anomalies within the brain following a MRI study that is performed for a reason other than for the evaluation of MS (multiple sclerosis).

Timeline

Start
2016-03-19
Primary completion
2021-03-31
Completion
2021-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator dimethyl fumarate Unknown 240 mg Oral

Indications